Kyaw Linn1, Alexander Fay2, Katherine Meddles3, Sara Isbell4, Phyo Nay Lin1, Cho Thair1, Jodi Heaps5, Robert Paul6, Soe Soe Mar3. 1. Pediatric Neurology Unit, Yangon Children's Hospital, Yangon, Myanmar. 2. Department of Pediatric Neurology, Washington University, St. Louis, Missouri. Electronic address: faya@neuro.wustl.edu. 3. Department of Pediatric Neurology, Washington University, St. Louis, Missouri. 4. Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis, Missouri. 5. Department of Psychology and Behavioral Neuroscience, University of Missouri, St. Louis, Missouri. 6. Missouri Institute of Mental Health, University of Missouri, St. Louis, Missouri.
Abstract
OBJECTIVE: We determined the effect of perinatally acquired HIV on neurocognition in Myanmar children treated with antiretroviral therapy by comparison to demographically matched seronegative children. BACKGROUND: Myanmar has one of the highest HIV-1 prevalence rates in Southeast Asia. Studies from other resource-poor countries have shown that HIV-infected children differ in socioeconomic, nutritional and caregiver status compared to normal controls. Some vertically infected orphans in Myanmar reside separately from HIV-uninfected children in separate orphanages, thus the demographic variables of interest are naturally controlled. This study provides a unique evaluation of the neurocognitive effects of HIV in children, with control over key demographic variables. We hypothesized that HIV-infected orphans would perform significantly worse on cognitive indices compared with HIV-negative orphans. DESIGN/ METHODS: A battery of cognitive tests sensitive to HIV-associated impairments in children was administered to 28 perinatally acquired HIV-positive children and 31 HIV-negative children from two orphanages in Myanmar; 21 children from each cohort underwent testing at baseline and again after 12 months. RESULTS: Baseline comparison of the two groups indicated that the HIV-infected children performed poorly across all tests, with significant group differences in executive function, visuospatial reasoning, fine motor dexterity, and visual motor integration. On subsequent testing, both cohorts of children showed improvements across multiple domains, with no significant effect of age at treatment initiation. CONCLUSIONS: Our results demonstrate a strong effect of HIV infection on specific neurocognitive deficits in vertically infected children. Understanding viral and host determinants and timing and choice of antiretroviral therapy on cognition will be critical to preventing cognitive impairment of children with HIV.
OBJECTIVE: We determined the effect of perinatally acquired HIV on neurocognition in Myanmar children treated with antiretroviral therapy by comparison to demographically matched seronegative children. BACKGROUND: Myanmar has one of the highest HIV-1 prevalence rates in Southeast Asia. Studies from other resource-poor countries have shown that HIV-infectedchildren differ in socioeconomic, nutritional and caregiver status compared to normal controls. Some vertically infected orphans in Myanmar reside separately from HIV-uninfectedchildren in separate orphanages, thus the demographic variables of interest are naturally controlled. This study provides a unique evaluation of the neurocognitive effects of HIV in children, with control over key demographic variables. We hypothesized that HIV-infected orphans would perform significantly worse on cognitive indices compared with HIV-negative orphans. DESIGN/ METHODS: A battery of cognitive tests sensitive to HIV-associated impairments in children was administered to 28 perinatally acquired HIV-positive children and 31 HIV-negative children from two orphanages in Myanmar; 21 children from each cohort underwent testing at baseline and again after 12 months. RESULTS: Baseline comparison of the two groups indicated that the HIV-infectedchildren performed poorly across all tests, with significant group differences in executive function, visuospatial reasoning, fine motor dexterity, and visual motor integration. On subsequent testing, both cohorts of children showed improvements across multiple domains, with no significant effect of age at treatment initiation. CONCLUSIONS: Our results demonstrate a strong effect of HIV infection on specific neurocognitive deficits in vertically infectedchildren. Understanding viral and host determinants and timing and choice of antiretroviral therapy on cognition will be critical to preventing cognitive impairment of children with HIV.
Authors: C Paula Lewis-de Los Angeles; Paige L Williams; Yanling Huo; Shirlene D Wang; Kristina A Uban; Megan M Herting; Kathleen Malee; Ram Yogev; John G Csernansky; Sharon Nichols; Russell B Van Dyke; Elizabeth R Sowell; Lei Wang Journal: Brain Behav Immun Date: 2017-01-10 Impact factor: 7.217
Authors: Kathleen M Malee; Miriam C Chernoff; Patricia A Sirois; Paige L Williams; Patricia A Garvie; Betsy L Kammerer; Lynnette L Harris; Molly L Nozyce; Cenk Yildirim; Sharon L Nichols Journal: J Acquir Immune Defic Syndr Date: 2017-08-01 Impact factor: 3.731
Authors: Amelia E Van Pelt; Tyler M Moore; J Cobb Scott; Onkemetse Phoi; Lingani Mbakile-Mahlanza; Knashawn H Morales; Ruben C Gur; Shathani Rampa; Mogomotsi Matshaba; Elizabeth D Lowenthal Journal: AIDS Behav Date: 2022-02-19
Authors: Damalie Nalwanga; Victor Musiime; Paul Bangirana; Erika Phelps Nishiguchi; Andrew Kiggwe; Titus Ssesanga; John M Ssenkusu; Philippa Musoke; Sarah E Cusick Journal: BMC Pediatr Date: 2021-04-26 Impact factor: 2.125
Authors: J Cobb Scott; Amelia E Van Pelt; Allison M Port; Lucky Njokweni; Ruben C Gur; Tyler M Moore; Onkemetse Phoi; Ontibile Tshume; Mogomotsi Matshaba; Kosha Ruparel; Jennifer Chapman; Elizabeth D Lowenthal Journal: BMJ Open Date: 2020-08-26 Impact factor: 2.692